Nectin Therapeutics Secures $10 Million from GIBF to Propel Immunotherapy
Nectin Therapeutics has been honored with the esteemed European Innovation Council (EIC) Accelerator funding
Nectin expands Phase I trial of NTX1088 combination to global sites
Nectin Therapeutics Advances Ongoing Clinical Trial and Expands Sites to Israel
Nectin Therapeutics Adds Combination Therapy Arm and Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent
Myeloma Investment Fund invests in Nectin Therapeutics to evaluate multiple myeloma drug candidate
Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm
Merck and Nectin to Study Novel Anti-PVR Candidate with Keytruda
Nectin Doses First Subject in Phase I Solid Tumour Immunotherapy Trial
Nectin Therapeutics Enters Clinical Stage With Drug for Non-Responders to Checkpoint Inhibitors
MD Anderson VC Arm Joins $25M Funding Round for Cancer Drug Company
Nectin's Series A Hits $25M as Investors Support New Target for Solid Tumors | BioSpace
